Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 8/20 | 0.39 |
| ▸ | JAK2 | O60674 | 6/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24743061 | 0.80 | AURKA (0.42) | RETJAK2PAK4AURKAAURKB | |
| SCHEMBL24743079 | 0.78 | CDK2 (0.43) | RETAURKAAURKB | |
| SCHEMBL24742505 | 0.71 | CYP3A4 (0.40) | JAK2JAK3PAK4AURKAAURKB | |
| SCHEMBL24742001 | 0.70 | AURKA (0.43) | PAK4AURKAAURKBPLK4NTRK1 | |
| SCHEMBL24743112 | 0.70 | RET (0.40) | RETJAK2PAK4AURKAAURKB | |
| SCHEMBL24743027 | 0.70 | AURKA (0.43) | PAK4AURKAAURKBPLK4NTRK1 | |
| SCHEMBL24741941 | 0.67 | PLK4 (0.39) | PAK4AURKAAURKBPLK4NTRK1 | |
| SCHEMBL24743111 | 0.67 | RET (0.47) | RETPAK4AURKA | |
| SCHEMBL24743108 | 0.66 | HDAC3 (0.45) | RETAURKA | |
| SCHEMBL24743066 | 0.66 | HDAC3 (0.44) | RETJAK2JAK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022206888-A1 | CDK2 INHIBITORS AND USE THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-10-06 | — | — | WO | disclosed |